key: cord-0993018-976i3hi4
authors: Massart, Nicolas; Maxime, Virginie; Fillatre, Pierre; Razazi, Keyvan; Ferré, Alexis; Moine, Pierre; Legay, Francois; Voiriot, Guillaume; Amara, Marlene; Santi, Francesca; Nseir, Saad; Marque-Juillet, Stephanie; Bounab, Rania; Barbarot, Nicolas; Bruneel, Fabrice; Luyt, Charles-Edouard
title: Characteristics and prognosis of bloodstream infection in patients with COVID-19 admitted in the ICU: an ancillary study of the COVID-ICU study
date: 2021-12-24
journal: Ann Intensive Care
DOI: 10.1186/s13613-021-00971-w
sha: 611a0e231136c785be0d649b52797486ba42873a
doc_id: 993018
cord_uid: 976i3hi4

BACKGROUND: Patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-COV 2) and requiring intensive care unit (ICU) have a high incidence of hospital-acquired infections; however, data regarding hospital acquired bloodstream infections (BSI) are scarce. We aimed to investigate risk factors and outcome of BSI in critically ill coronavirus infectious disease-19 (COVID-19) patients. PATIENTS AND METHODS: We performed an ancillary analysis of a multicenter prospective international cohort study (COVID-ICU study) that included 4010 COVID-19 ICU patients. For the present analysis, only those with data regarding primary outcome (death within 90 days from admission) or BSI status were included. Risk factors for BSI were analyzed using Fine and Gray competing risk model. Then, for outcome comparison, 537 BSI-patients were matched with 537 controls using propensity score matching. RESULTS: Among 4010 included patients, 780 (19.5%) acquired a total of 1066 BSI (10.3 BSI per 1000 patients days at risk) of whom 92% were acquired in the ICU. Higher SAPS II, male gender, longer time from hospital to ICU admission and antiviral drug before admission were independently associated with an increased risk of BSI, and interestingly, this risk decreased over time. BSI was independently associated with a shorter time to death in the overall population (adjusted hazard ratio (aHR) 1.28, 95% CI 1.05–1.56) and, in the propensity score matched data set, patients with BSI had a higher mortality rate (39% vs 33% p = 0.036). BSI accounted for 3.6% of the death of the overall population. CONCLUSION: COVID-19 ICU patients have a high risk of BSI, especially early after ICU admission, risk that increases with severity but not with corticosteroids use. BSI is associated with an increased mortality rate. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13613-021-00971-w.

Background As a consequence of severe acute respiratory syndrome coronavirus-2 (SARS-COV 2) epidemic, intensive care units (ICU) worldwide faced a surge of critically ill patients who are at risk of developing bacterial infections, in particular patients requiring mechanical ventilation (MV) [1] [2] [3] . Although pulmonary bacterial infections (co-infection and nosocomial infections) have been extensively studied in ICU patients [1, 2, 4] , conflicting results are reported, due to differences in infection definitions. Conversely, bloodstream infection (BSI) have been less studied, and among the 10 studies published to date [3, [5] [6] [7] [8] [9] [10] [11] [12] , only 2 focused on ICU patients [3, 9] . The first one was a single-center study that included 78 patients, and found a high incidence of BSI (45 episodes in 31 patients, e.g., 39% of patients with at least one episode) [9] . The second one, a case-cohort study that matched 235 ICU patients with coronavirus disease 2019 to 235 patients without, found that COVID-19 patients had a higher rate of BSI than non-COVID-19 patients [3] . A third study included 100 BSI out of a cohort of 2005 patients, but although most bacteremia occurred in ICU patients, the baseline population was not exclusively hospitalized in the ICU [11] . Therefore, data regarding BSI (incidence, risk factors and prognosis) specifically in ICU patients are lacking.

We conducted this study to evaluate the incidence, risk factors and prognosis of hospital acquired BSI in patients with SARS-CoV-2 pneumonia hospitalized in the ICU.

We performed an ancillary analysis of the COVID-ICU study. COVID-ICU was a multi-center, observational, and prospective cohort study conducted in 149 ICUs from 138 centers, across three countries (France, Switzerland, and Belgium) and has been described elsewhere [13] . It received approval from the ethical committee of the French Intensive Care Society (CE-SRLF 20-23) and Swiss and Belgium ethical committees following local regulations. All patients or close relatives were informed that their medical data were anonymously included in the COVID-ICU cohort. Patients and relatives had the possibility not to participate in the study. In case of refusal, the data were not collected accordingly. This manuscript follows the STROBE statement for reporting cohort studies.

For this report, we restricted the analysis to patients in whom the BSI status (yes/no) and day 90 status were known: these data were available for 4010 out of the 4747 patients included in the COVID-ICU study [13] . Data regarding incidence and risk factors were analyzed from this population. In a second set of analysis, to assess the attributable mortality of BSI, we matched 537 patients with BSI to 537 controls (patients without BSI) using a propensity score matching [14] .

Day-1 was defined as the first day when the patient was in ICU at 10:00 AM. Each day, the study investigators completed a standardized electronic case report form. Baseline information collected at ICU admission were: age, gender, body mass index (BMI), active smoking, Simplified Acute Physiology Score (SAPS) II score [15] , Sequential Organ Failure Assessment (SOFA) [16] , comorbidities, immunodeficiency (if present), the date of the first symptom, dates and times of hospital and ICU admissions, and presence or not of co-infection at ICU admission [17] . Acute respiratory distress syndrome (ARDS) severity was assessed using Berlin definition [18] . Data collected daily from day 1 to day 15 and then at days 21, 45, 60 and 90 were the following: use of immunomodulatory drugs (interferon, tocilizumab or monoclonal antibodies), antiviral drug, antibiotics, anticoagulants and glucocorticoids; occurrence of BSI or ventilatorassociated pneumonia (VAP); procedures during ICU stay (mechanical ventilation (MV), extracorporeal membrane oxygenation (ECMO), renal replacement therapy (RRT)). The number of days at risk for BSI was the number of days in hospital from the 48th hour of stay until ICU discharge for patients without BSI or until the first occurrence of BSI for patients with BSI.

For each positive blood culture, investigators could point out the micro-organisms responsible for infection among a restricted list: Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, Streptococcus pneumonia, Group A or B Streptococcus, Enteroccoccus spp., methicillin-susceptible Staphylococcus aureus, methicillinresistant Staphylococcus aureus, Haemophilus influenza, anaerobes or other. Therefore, "other" denotes all microorganisms not present in the preceding list and were not specified. Since some patients may have polymicrobial blood culture, investigators could declare as many microorganisms that needed for a single blood sample.

The following outcomes were also recorded: occurrence of thrombosis [19] , duration of MV, vital status at ICU and hospital discharge and 28, 60 and 90 days after ICU admission. [20] . ICU-free days at day 90 was defined as the number of days alive and outside the ICU at day 90 after ICU admission.

Statistical analysis was performed with the statistical software R 3.4.3. Incidence rate and prevalence were expressed with the 95 percent confidence interval (95% CI). Categorical variables were expressed as number (percentage) and continuous variables as median and interquartile range [IQR] . When appropriate, the chisquare test and the Fisher's exact test were used to compare categorical variables. The Mann-Whitney U test and the Wilcoxon test were used for continuous variables when applicable. All tests were two-sided, and a P value less than 0.05 was considered statistically significant. Competitive risk analysis was used to estimate the probability of developing a BSI, with discharge and death being competing events. Using the "cmprsk" package we performed a Fine and Gray model to estimate sub-distribution hazard ratio (sdHR) of ICU death [14] . Therefore, sdHR > 1 indicates that those with exposure will be seen to have a quicker time to BSI. Conversely, a sdHR < 1 indicates a longer time before BSI onset for those exposed. A multivariable cox proportional hazard model was used for survival analysis. Variables associated with event (either BSI or death) with a p value < 0.2 in univariate analysis were included in multivariable model. Of note, for outcome comparison, only the first BSI was taken into account.

Because BSI acquisition was considered as a transition state from admission to discharge or death, patients with BSI were included in the group with BSI from first BSI onset only, to take into account immortal time bias associate with exposure.

To draw unbiased marginal estimates of exposure effect, a propensity-score matched analysis was performed. Propensity score was calculated for each patient and correspond to his probability to develop BSI and to die. As potential confounders, we included for propensity-score calculation all non-redundant variables associated with BSI (event) or death (outcome) with p value ≤ 0.05 in the Fine and Gray (BSI) or Cox model (death) multivariable analysis. Then, using the "MatchIt" package, a k-nearest neighbor algorithm was used for propensity-score matching with a 1:1 ratio: each patient with BSI was matched with 1 patient without BSI with the nearest propensity-score. The balance between matched groups was evaluated by the analysis of the standardized differences before and after weighting. A post-matching difference < 0.1 was considered as an optimal bias reduction. Multivariable Cox proportional hazard model and Kaplan-Meier survival curves were used for survival analysis in the propensitymatched analysis.

Among the 4747 patients included in the COVID-ICU database, 4010 had all data available and were included in the current analysis ( Fig. 1 [3] [4] [5] [6] [7] [8] , respectively. ARDS criteria were objective in 3231 (81%), of whom 776 (19%), 1,635 (41%) and 820 had mild, moderate and severe ARDS, respectively. Finally 283 (7%) had a bacterial coinfection on admission.

Among these 4,010 patients, 780 (19.5%) experienced a total of 1066 episodes of BSI (1 [1, 2] episode per patient with BSI) through 103,293 patients-days at risk. Therefore, incidence rate was 10.3 BSI per 1000 patients-days. First episode of BSI occurred after a median [IQR] of 9 [5] [6] [7] [8] [9] [10] [11] [12] [13] days after hospital admission (Fig. 2) . BSI was considered as ICU-acquired in 714 (92%) of patients with at least one BSI episode. Baseline characteristics of patients, according to their status (BSI or not) are displayed in 

Risk factors for BSI in univariate and multivariable analysis are given in Table 2 . Higher SAPS II, male gender, longer time from hospital to ICU admission, antiviral drug before admission, intubation during period at risk for BSI, renal replacement therapy during period at risk for BSI, antibiotic use prior to BSI were independently associated with occurrence of BSI and interestingly, the risk to develop BSI decreased over time (Table 2 and Fig. 2 ).

Risk factors associated with death at day 90 are reported in Table 3 . After adjusting for potential confounders using Cox model multivariable analysis, BSI occurring during hospital stay remained associated with day-90 mortality (HR 1.28, 95% CI 1.05-1.56). In a sensitive analysis in which BSI patients in whom the micro-organism responsible for infection was notified as "others" were excluded (n = 434), BSI remained independently associated with a shorter time to death (aHR1.41, 95% CI 1.08-1.84). Univariate and multivariable Cox analysis of factors associated with day-90 death in the 780 patients with BSI is shown in Additional file 1: Table S3 . Age, frailty scale [21] , SOFA score the day of BSI, co-infection at admission, antibiotic and tocilizumab use during period at risk for BSI were associated with increased risk of day-90 death.

None redundant baseline characteristics independently associated with day-90 death and/or BSI (i.e., SAPS II, frailty scale, ARDS severity, hypertension, diabetes mellitus, male gender, time from hospital admission to ICU admission, antiviral before admission, intubation before admission, nurse/patients ratio) were included for propensity score calculation. Only patients without missing data regarding these variables were included for matching procedure (Fig. 1) . Thereafter 537 patients with BSI were matched with 537 without BSI. Density of propensity scores in each groups are reported in Additional file 1: Fig. S1 , and baseline characteristics were well balanced (Additional file 1: Table S2) .

Outcomes of matched patients with and without BSI are given in Table 4 : patients with BSI had worse outcomes than patients without BSI with longer hospital and ICU length of stay, less day-90 ICU-and ventilator-free days, and higher mortality rate. Probability of death with time was higher among patients with BSI (HR 1.26; 95% CI [1.03-1.54]) (Fig. 3) . Relative risk of death was 1.19 and number needed to harm was 16. Therefore, attributable mortality fraction of BSI in the overall population (n = 4010) was 3.6%.

In this study, we show that among a large population of COVID-19 patients requiring ICU, BSI was frequent, occurring in 19.5% of patients. Various risk factors for BSI were identified, with higher SAPS II, male gender, longer time from hospital to ICU admission, antiviral drug before admission, intubation being associated with increased risk of BSI. Another result was that BSI was independently associated with increased day-90 mortality.

Several studies having evaluated BSI in COVID-19 patients have been published to date, most of them mixing ICU and non-ICU patients, with incidence of BSI ranging from 2.7 to 5.6% [5, 6, 8, 10, 11] . Only 2 studies focused on ICU patients: a single-center study found that 31 out of 78 patients (39%) experienced at least one episode of BSI [9] ; and a larger multicenter study of 235 COVID-19 patients found a 14.9% incidence of BSI [3] . In this study, the authors matched their COVID-19 patients to 235 ICU patients without COVID-19, and they found a lower rate of BSI in patients without COVID (3.4%). However, they did not evaluate the mortality attributable to BSI. A more recent multicenter case-control study matched, among 2,005 patients with COVID-19, 100 patients with BSI to 100 patients without BSI (matched on age, gender, and severity) [11] . The authors found that immunomodulatory drugs were not associated with an increased risk of BSI, but that BSI was associated with a higher mortality risk. However, this study did not focus on ICU patients. Our results are line with these data and complete them: our incidence of bacteremia was close to that of the largest ICU study published to date [3] , and we showed for the first time that ICU-acquired BSI was associate with an excess death rate. This attributable mortality was in line with previous reports in non patients, ranking from 2.1 to 5.2% [14, 22] . Further studies are needed to better understand association between BSI and death in critically ill patients.

Given the high number of patients included in the COVID-ICU study and the high number of BSI, we were able to explore risk factors for BSI in ICU patients. Beyond traditional risk factors, unexpected results were observed for two variables: renal replacement therapy and number of day at risk being associated with lower risk of developing BSI. For the first variable, we assume that patients needing renal replacement therapy have a high probability of early death, competing with BSI occurrence. Similarly, use of epinephrine was not associated with an increased risk of BSI. For the second one, it suggests that patients have a higher risk of BSI soon after admission, while facing a more severe condition, whereas this risk decreases over time, with clinical improvement. Caregivers should be careful about BSI early after admission. Interestingly, corticosteroids use was not associated with increased risk of BSI. In a recent multicenter observational study, use of dexamethasone was not associated with an increased risk of BSI [23] . Similar results were found in another case-control study [11] . Data regarding immunomodulatory drug use and risk of BSI are discordant in ICU patients: a recent randomized placebo-controlled trial found no increased risk of infection with tocilizumab use [24] . Abelenda-Alonso et al. found no association between tocilizumab use and BSI [11] , whereas Buetti et al. found an association between its use and BSI; however, in that study, the small sample size limits any firm conclusion [3] . In our study, although few patients received tocilizumab, its use was not associated with an increased risk of BSI. However, those experiencing BSI after tocilizumab use had an increased mortality as compared with BSI patients who did not received this agent. Combined with the lack of effect of anti-IL6 drugs in the most severe patients, their use should be cautiously outweighed in ICU patients. Similarly, BSI patients with previous antibiotic exposure had an increased risk of death. We hypothesized that antibiotic pressure selected resistant microorganisms in which empiric therapy was more likely to fail. This result supports a strict antibiotic stewardship program in COVID-19 setting.

Several limitations of our study should be underlined. First, some data are missing, which is inherent to this kind of multicenter observational study [13] . In particular, the main objective of the COVID-ICU study was not to evaluate infectious complications of ICU patients suffering from COVID-19. Therefore, we lack of important data, such as pathogen responsible for BSI (the list of bacteria available was restricted and for more than 50% of BSI episodes, pathogen responsible for infection is not known). Other relevant missing values were date of BSI occurrence after day 21 (for 40 patients, BSI occurred after day 21 but without additional precision), susceptibility of pathogen responsible for infection (wild type, multi-drug resistant…) appropriateness and duration of antimicrobial treatment. Second, this study was performed during the first wave, between March and May 2020. Since care of COVID-19 ICU patients has changed with improvement over time, and differ from one country to another, results might be different in different countries and among different waves of the pandemic. In particular, with the widespread use of corticosteroids and the increased use of anti-IL-6 drugs, incidence of BSI and outcomes may be different. Third, we defined BSI as a single positive blood culture. For some pathogens such as Staphylococcus epidermidis, 2 blood cultures taken apart are required to define BSI. We, therefore, might have overestimated the rate of BSI. However, the rate of BSI in our study was similar to other reports [3, 11] and lower than other [9] . Moreover, other studies found a high rate of BSI due to Staphylococcus epidermidis [12] . In our study, BSI patients infected with unknown pathogen and those infected with an identified microorganism had similar outcomes, and should be both similarly considered. Fourth, as BSI occurred during ICU stay, we should acknowledge immortal time bias [25] . However, this bias would lead to underestimation of mortality risk associated with BSI, since patients experiencing this event are those surviving longer enough, whereas those who died early have short time of exposition but were even included in control group.

In conclusion, BSI is a frequent complication of critically ill COVID-19 patients, especially early after ICU admission and is associated with increased severity at admission but not with corticosteroids use. BSI is associated with an increased mortality rate.

The online version contains supplementary material available at https:// doi. org/ 10. 1186/ s13613-021-00971-w. 

Yanis Kouchit), Centre Hospitalier d'Orléans

Centre Hospitalier Intercommunal Toulon

Eve Marie Maiziere), Centre Hospitalier des Pays de Morlaix

Carole Schwebel, Anaïs Dartevel, Louis-Marie Galerneau)

Hôpital Privé du Vert Galant

Centre Hospitalier Victor Jousselin

Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study

Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study

COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network. Intensive Care Med

Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease

Clinical characteristics of Covid-19 in New York City

Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting

Bacteremia and blood culture utilization during COVID-19 surge in New York City

Predominance of hospital-acquired bloodstream infection in patients with Covid-19 pneumonia

Bloodstream infections in critically ill patients with COVID-19

Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia

Immunomodulatory therapy, risk factors and outcomes of hospitalacquired bloodstream infection in patients with severe COVID-19 pneumonia: a Spanish case-control matched multicenter study (BACTCOVID)

Risk factors and outcomes of hospitalized patients with severe Coronavirus Disease 2019 (COVID-19) and secondary bloodstream infections: a multicenter casecontrol study

Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study

Attributable mortality of ICU acquired bloodstream infections: a propensity-score matched analysis

A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on sepsis-related problems of the European Society of Intensive Care Medicine

Characteristics, management, and prognosis of elderly patients with COVID-19 admitted in the ICU during the first wave: insights from the COVID-ICU study: prognosis of COVID-19 elderly critically ill patients in the ICU

Acute respiratory distress syndrome: the Berlin Definition

Extracorporeal membrane oxygenation induces early alterations in coagulation and fibrinolysis profiles in COVID-19 patients with acute respiratory distress syndrome

Preemptive ganciclovir for mechanically ventilated patients with cytomegalovirus reactivation

Lactate is associated with mortality in very old intensive care patients suffering from COVID-19: results from an international observational study of 2860 patients

Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality

Impact of dexamethasone on the incidence of ventilator-associated pneumonia and blood stream infections in COVID-19 patients requiring invasive mechanical ventilation: a multicenter retrospective study

Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19

Attention to immortal time bias in critical care research

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

We thank all investigators from the COVID-ICU Bacteremia Study Group, who were involved in the development of this study: S Nseir, K 

Authors' contributions NM, VL, PF, FB and CEL designed the study, interpreted the data and wrote the manuscript. NM and PF performed statistical analysis. All authors made significant intellectual concept. All authors read and approved the final manuscript.

This study was funded by the Fondation APHP and its donators through the program "Alliance Tous Unis Contre le Virus", the Direction de la Recherche Clinique et du Développement, and the French Ministry of Health and the foundation of the University hospitals of Geneva, Geneva, Switzerland. The funder had no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. This study was funded by Ministère des Affaires Sociales, de la Santé et des Droits des Femmes.

The data sets generated during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate Human research ethics committee approval for the study was the ethical committee of the French Intensive Care Society (CE-SRLF 20-23) following our local regulations.

Competing interests CEL has served as consultant for Bayer Healthcare, Carmat and Thermo Fisher Brahms, and received lecture fees from MSD, Aerogen and BioMérieux, outside the submitted work. The other authors have no conflicts of interest to declare in relationship to this manuscript.